A day is a long time to study a donated human brain. Bexorg thinks it’s still too short. On 7 October, the Connecticut-based ...

Adjusting for how advanced patients’ disease was at the start lifts the Phase 2 result. The method was added after the trial ...

German biotech MODAG won for pairing a CE-marked diagnostic with a drug candidate that targets the same protein.

Buck Institute’s Eric Verdin joins clinic leaders to tackle the ‘luxury diagnostic’ trap and the push for standardized care.

Shmouni and Koehl Robinson unpack peptide medicine, from GLP-1s and BPC-157 to evidence, safety, regulation and personalized ...

BodySpec’s new storefront targets muscle loss from GLP-1 weight loss drugs, with scans said to take about 12 minutes.

VectorY is growing PIONEER-ALS from 12 to 36 participants to test VTx-002, an antibody therapy aimed at the protein TDP-43.

A Censuswide survey commissioned by PortionIQ finds confidence is lower among longer-term users, though it’s a snapshot from one brand.

Forget the diagnosis count. The researcher who helped the WHO reframe aging says function, not disease, is the better yardstick.

A new preprint links the company’s cell therapy to less brain inflammation in Alzheimer’s, just as it heads out on an ...

The whole-body scan company is launching a research network with 50+ institutions. Early findings come with some big open questions. Seven in every 100 people. That’s how many showed a clinically ...